Welcoming Three New Startups to the LvlUp Ventures Ecosystem
At LvlUp Ventures, we look for founders building ambitious solutions to meaningful problems—teams that combine technical depth, clear market insight, and early evidence that customers are already paying attention.
Today, we're excited to welcome three new companies to the portfolio: DOSE, Kreativio, and Universum Therapeutics.
While they operate in very different markets, each company is leveraging technology in a unique way to address large, underserved opportunities.
DOSE: Building the Operating System for ADHD Support
Millions of people with ADHD struggle with challenges that occur in real time—emotional dysregulation, overwhelm, rejection sensitivity, and task paralysis. Most existing tools focus on planning and organization. DOSE is focused on what happens in the moment.
The platform combines AI-powered support, behavioral frameworks, and productivity tools designed specifically for adults and youth with ADHD.
What stood out to us was the strength of the early user engagement. DOSE has already completed more than 1,300 coaching sessions, generated 500+ waitlist signups, achieved a 90% invite-to-use conversion rate, and reported 100% retention after the first session. Those metrics suggest a product solving a problem users feel immediately.
Kreativio: Turning AI-Generated Ideas Into Physical Products
The next generation of consumer creativity won't stop at digital content—it will extend into physical products.
Kreativio is building a mobile-first platform that allows users to generate custom 3D products from simple text prompts. By combining AI design tools with a distributed manufacturing network, the company makes custom product creation accessible to everyday consumers without requiring CAD expertise or specialized hardware.
What impressed us most is that the team has already validated demand before launch. Through KreativioLab, they've generated more than $55,000 in revenue, completed over 1,500 sales across four channels, built a 450+ person waitlist, and established partnerships with multiple print-farm affiliates. The marketplace fundamentals are already taking shape.
Universum Therapeutics: Reimagining Drug Discovery Across Diseases
Drug discovery remains one of the most expensive and time-consuming processes in healthcare. Universum Therapeutics is approaching the problem from a different angle.
The company is building an AI-powered discovery platform that identifies conserved biological pathways across oncology, infectious disease, and virology. By validating targets across both human and pathogen biology, the platform aims to accelerate discovery while expanding the potential applications of each breakthrough.
Even at an early stage, the technical progress is notable. The team has computationally screened 3,904 covalent fragments, identified five tier-1 candidates, and confirmed two dual-target hits spanning both human and pathogen orthologs. Their approach represents a highly ambitious attempt to create leverage across multiple therapeutic categories from a single discovery engine.
These companies operate in different industries—mental health, consumer AI, and biotechnology—but they share several characteristics we consistently seek in founders:
- Large and growing market opportunities
- Clear technical differentiation
- Early validation from users, customers, or partners
- Founders with deep conviction and domain expertise
- Products capable of creating meaningful long-term impact
We're proud to support the teams at DOSE, Kreativio, and Universum Therapeutics as they enter their next stage of growth.
Welcome to the LvlUp Ventures ecosystem. We're excited to be part of the journey. 🚀
